Top Page
Bioceres Crop Solutions
(NASDAQ:BIOX)
Bioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)
Bioceres Crop Solutions Business Overview & Revenue Model
Bioceres Crop Solutions Key Performance Indicators (KPIs)
Shows how much revenue each business segment contributes, highlighting areas of strength and potential growth within Bioceres Crop Solutions' diverse operations.
The FlyBioceres Crop Solutions Earnings Call Summary
Bioceres Crop Solutions Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 318.23M | 333.30M | 464.83M | 419.45M | 328.46M | 206.70M |
| Gross Profit | 124.48M | 130.20M | 181.59M | 180.25M | 126.44M | 90.88M |
| EBITDA | 17.14M | 13.59M | 55.45M | 72.38M | 47.91M | 43.70M |
| Net Income | -52.83M | -51.80M | 3.24M | 18.78M | -7.20M | -6.87M |
Balance Sheet | ||||||
| Total Assets | 734.88M | 763.65M | 852.55M | 818.06M | 518.22M | 394.59M |
| Cash, Cash Equivalents and Short-Term Investments | 16.61M | 34.74M | 56.17M | 60.05M | 38.61M | 46.78M |
| Total Debt | 267.74M | 276.61M | 270.95M | 257.41M | 169.79M | 174.58M |
| Total Liabilities | 455.83M | 468.43M | 501.17M | 487.56M | 359.92M | 304.30M |
| Stockholders Equity | 249.38M | 262.81M | 315.30M | 298.85M | 127.61M | 67.74M |
Cash Flow | ||||||
| Free Cash Flow | 36.54M | 35.30M | 18.93M | -19.97M | -26.51M | -20.13M |
| Operating Cash Flow | 45.23M | 49.91M | 41.72M | 2.59M | -17.52M | -6.21M |
| Investing Cash Flow | -7.67M | -6.13M | -28.73M | -25.73M | 2.90M | -8.31M |
| Financing Cash Flow | -56.76M | -50.71M | -10.06M | 32.95M | 14.82M | 7.36M |
Bioceres Crop Solutions Technical Analysis
Bioceres Crop Solutions Risk Analysis
Bioceres Crop Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
48 Neutral | $37.94M | -0.58 | -20.52% | ― | -27.90% | -4194.67% | |
45 Neutral | $149.17M | -1.28 | -40.84% | ― | -4.29% | -276.74% | |
45 Neutral | $3.29M | -0.47 | -64.08% | ― | -1.80% | 15.74% | |
45 Neutral | $106.48M | -6.79 | -200.22% | ― | 45.88% | 43.12% | |
45 Neutral | $142.10M | -0.33 | ― | ― | ― | ― | |
42 Neutral | $14.69M | -1.11 | ― | ― | -21.82% | -104.92% |
Bioceres Crop Solutions Corporate Events
On January 20, 2026, Bioceres Crop Solutions reported that a UCC foreclosure sale was held involving collateral pledged by its affiliates Pro Farm Group, Inc. and Pro Farm Michigan Manufacturing, LLC under notes originally issued in August 2022 and amended in June 2025. The only qualified bid came from PFG Holdings Corp., a joint venture formed by the noteholders, which submitted a $15 million credit bid and was declared the winning bidder after no competing offers emerged at the virtual auction attended by company representatives and counsel. Bioceres has formally disputed the alleged defaults that triggered the foreclosure and the commercial reasonableness of the sale, signaling potential legal challenges ahead and creating uncertainty around the final ownership and valuation of the Pro Farm-related assets for creditors and other stakeholders.
The most recent analyst rating on (BIOX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.
On January 8, 2026, Bioceres Crop Solutions Corp. filed a Form 6-K announcing that it has convened its 2026 Annual General Meeting of shareholders for January 30, 2026, to be held in New York and accessible virtually. Shareholders of record as of January 5, 2026, are invited to vote on approving the consolidated financial statements for the fiscal year ended June 30, 2025, electing four directors—Federico Trucco, Duraiswami (“D”) Narain, Antonio Simon Vumbaca and Yogesh Mago—to serve until the 2027 annual meeting, and ratifying the appointment of Price Waterhouse & Co. S.R.L. as the company’s independent registered public accounting firm. The meeting will feature telephone and web-based access, underscoring Bioceres’ efforts to facilitate participation by its global investor base and to reaffirm its governance and audit framework under Cayman Islands law and U.S. reporting standards.
The most recent analyst rating on (BIOX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.
On December 31, 2025, Bioceres Crop Solutions announced leadership changes, naming agribusiness veteran Ezequiel Simmermacher as chief financial officer effective January 5, 2025, and appointing experienced industry executive Duraiswami (“D”) Narain to its board of directors as of December 29, 2025, following the December 26, 2025 resignation of longtime director Natalia Zang. The reshaped leadership, which includes Narain assuming Zang’s former committee roles and chairing the audit committee, is expected to strengthen Bioceres’ financial stewardship and governance as it prepares proxy materials for mailing in January 2026 and seeks to maintain continuity by proposing the reappointment of its current board through the 2027 annual general meeting.
The most recent analyst rating on (BIOX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.
On December 18, 2025, Bioceres Crop Solutions Corp. reported that a New York State court, hearing a lawsuit brought by several noteholders over alleged defaults on convertible and non-convertible notes issued under 2022 note purchase agreements, partially granted the plaintiffs’ motion to protect pledged collateral and denied the company’s cross-motion to halt a planned foreclosure auction. The court ordered Bioceres and affiliated Pro Farm entities not to transfer or encumber any collateral securing the notes, and, following that decision, the noteholders proposed, and Bioceres agreed on December 20, 2025, to adjourn the foreclosure sale from December 22, 2025 to January 19, 2026 to enable a more orderly and commercially reasonable sale process, with the company committing to cooperate by facilitating due diligence and access for potential bidders while expressly maintaining its dispute of the alleged defaults and reserving all rights to challenge the sale and related proceedings.
The most recent analyst rating on (BIOX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.
Bioceres Crop Solutions Corp. released its unaudited interim condensed consolidated financial statements for the periods ending September 30, 2025, and June 30, 2025. The financial report indicates a decrease in total assets from $763.6 million to $734.9 million, and a reduction in total liabilities from $468.4 million to $446.5 million. This financial update provides stakeholders with insights into the company’s current financial health and operational adjustments over the recent quarter.
The most recent analyst rating on (BIOX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.
Bioceres Crop Solutions reported its fiscal first quarter 2026 financial results, with total revenues of $77.5 million, marking a 17% decline year-over-year. Despite the revenue drop due to strategic reductions in low-margin sales and seed model transition, the company achieved a gross margin expansion from 40% to 47%, reflecting a more profitable product mix. The net loss widened to $7.5 million, but operating profit and adjusted EBITDA saw significant improvements, driven by cost discipline and restructuring efforts. The company remains focused on enhancing capital structure and financial flexibility amidst challenging market conditions in Argentina.
The most recent analyst rating on (BIOX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.
On November 10, 2025, Bioceres Crop Solutions received an Acceleration Notice from its noteholders, alleging defaults under its Convertible and Non-Convertible Note Purchase Agreements. Subsequently, on November 11, 2025, these noteholders initiated legal proceedings against Bioceres in the New York Supreme Court, seeking full payment of outstanding amounts. Bioceres disputes the allegations and intends to defend its position vigorously, reserving all rights against the noteholders.
The most recent analyst rating on (BIOX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.
On November 5, 2025, Bioceres Crop Solutions Corp. announced the appointment of Mr. Simon Vumbaca to its Board of Directors and Mr. Alejandro Villafane as the Principal Accounting Officer. Mr. Vumbaca brings expertise in high-stakes strategies and governance, while Mr. Villafane will oversee the company’s accounting functions. These appointments are expected to strengthen Bioceres’ strategic and financial leadership, potentially enhancing its market position and operational resilience.
The most recent analyst rating on (BIOX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.